VVP808 is a novel agent that improves glucose tolerance in DIO mice

Spolding, B., Connor, T., DeVries, M., Wanyonyi, S., Cooper, A., Lee, S., Molero, J. C. and Walder, K. 2008, VVP808 is a novel agent that improves glucose tolerance in DIO mice, in ADS & ADEA 2008 : Proceedings of the 2008 ADS & ADEA annual scientific meeting, ADS & ADEA, [Melbourne, Vic.].

Title VVP808 is a novel agent that improves glucose tolerance in DIO mice
Author(s) Spolding, B.
Connor, T.
DeVries, M.
Wanyonyi, S.
Cooper, A.
Lee, S.
Molero, J. C.
Walder, K.
Conference name ADS & ADEA annual scientific meeting (2008 : Melbourne, Victoria)
Conference location Melbourne, Victoria
Conference dates 28-30 August 2008
Title of proceedings ADS & ADEA 2008 : Proceedings of the 2008 ADS & ADEA annual scientific meeting
Editor(s) [Unknown]
Publication date 2008
Publisher ADS & ADEA
Place of publication [Melbourne, Vic.]
Summary As the prevalence of diabetes mellitus continues to increase, there is an urgent need to discover new, effective treatment strategies to combat this disorder. In this study, we tested a novel agent, VVP808, which we previously demonstrated has insulin-sensitising properties (as measured by an increase in insulin-stimulated glucose uptake in 3T3-L1 adipocytes). A dose-ranging study was performed (10-100mg/kg/d) in C57BL/6J mice that had been fed a high-fat diet (45% of energy) for 12 weeks. VVP808 was administered by single daily oral gavage for a period of 16 days. Body weight, food intake and water intake were measured daily, whilst fasting blood glucose and plasma insulin levels were measured at the beginning and end of the study, with an intra-peritoneal glucose tolerance test (ipGTT) performed on day -1 and day 13. Administration of VVP808 to diet-induced obese (DIO) mice caused a strong dose-dependent improvement in glucose tolerance. There was a 34-42% reduction in the blood glucose area under the curve (AUC) at doses of 20mg/kg, 50mg/kg and 100mg/kg VVP808 (p=0.02-0.005). Administration of VVP808 resulted in a small but significant reduction in body weight in the 50mg/kg and 100mg/kg treated animals relative to vehicle (p=0.01 and 0.001 respectively). This decrease in body weight was associated with a reduction in food intake for the 100mg/kg treated animals only. Epididymal fat pad weight was significantly reduced in animals treated with 100mg/kg VVP808 (p=0.01). Furthermore, treatment with VVP808 for 16 days resulted in a highly significant dose-dependent reduction in fasting blood glucose levels relative to vehicle treated animals (p= 0.01-0.001). In conclusion, our data showed that VVP808 acts in a dose-dependent manner to reduce fasting blood glucose levels and improve glucose tolerance. These data suggest that VVP808 is an interesting new agent with potential for development as a novel therapeutic for type 2 diabetes.
Language eng
Field of Research 110306 Endocrinology
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category E1.1 Full written paper - refereed
ERA Research output type X Not reportable
Copyright notice ©2008, ADS & ADEA
Persistent URL http://hdl.handle.net/10536/DRO/DU:30025759

Document type: Conference Paper
Collections: School of Medicine
Institute for Technology Research and Innovation
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Access Statistics: 529 Abstract Views  -  Detailed Statistics
Created: Thu, 25 Mar 2010, 14:56:59 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.